Abciximab biosimilar - Pfenex

Drug Profile

Abciximab biosimilar - Pfenex

Alternative Names: Monoclonal antibody 7E3 - Pfenex

Latest Information Update: 02 Jun 2015

Price : $50

At a glance

  • Originator Pfenex
  • Class Antiplatelets; Fab fragments; Ischaemic heart disorder therapies; Monoclonal antibodies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Vascular disorders

Most Recent Events

  • 01 Jan 2015 No development reported for Vascular disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top